TaiMed Biologics pioneered Trogarzo®, the first FDA- and EMA-approved long-acting monoclonal antibody (mAb) for HIV. Today, we’re advancing our next-generation regimen, TMB-365/380, which has received Fast Track designation from the FDA and was recently presented as a Late-Breaking study at CROI 2025, highlighting its strong potential to redefine HIV treatment.

With decades of experience in antibody development and manufacturing, TaiMed also offers comprehensive CDMO services, supporting global partners from early-stage development through to commercial launch.

Let’s connect at BIO 2025 in Boston to shape the future of global health—together.

📍 Booth #2083
Partner with us in HIV innovation and biomanufacturing.
📩 To schedule a meeting, contact us at cdmo@taimedbio.com